Literature DB >> 12544532

Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.

Michael T Kram1, Louis D May, Stephen Goodman, Sharon Molinas.   

Abstract

Behçet's disease is a chronic inflammatory disease characterized by recurrent oral aphthae and systemic manifestations. Gastrointestinal involvement is rare. We report a case of ileocolitis secondary to Behçet's successfully treated with tumor necrosis factor-alpha antibody (infliximab) therapy. To our knowledge this is the second reported case of Behçet's ileocolitis successfully treated with anti-tumor necrosis factor therapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12544532     DOI： 10.1007/s10350-004-6506-4

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN： 0012-3706            Impact factor:   4.585


  17 in total

Review 1.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

2.  Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease.

Authors:  Y Imamura; M S Kurokawa; H Yoshikawa; K Nara; E Takada; C Masuda; S Tsukikawa; S Ozaki; T Matsuda; N Suzuki
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 3.  Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.

Authors:  Yehyun Park; Jae Hee Cheon
Journal:  Curr Gastroenterol Rep       Date:  2020-03-19

4.  Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial.

Authors:  H Al-Rayes; R Al-Swailem; M Al-Balawi; N Al-Dohayan; S Al-Zaidi; M Tariq
Journal:  Rheumatol Int       Date:  2008-05-22       Impact factor: 2.631

5.  Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.

Authors:  Sook Hee Chung; Soo Jung Park; Sung Pil Hong; Jae Hee Cheon; Tae Il Kim; Won Ho Kim
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

6.  Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.

Authors:  Salvatore Gulli; Carlo Arrigo; Loredana Bocchino; Lucia Morgante; Donatella Sangari; Irene Castagna; Gian Filippo Bagnato
Journal:  BMC Musculoskelet Disord       Date:  2003-08-28       Impact factor: 2.362

7.  The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.

Authors:  Tadakazu Hisamatsu; Fumiaki Ueno; Takayuki Matsumoto; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Fumihito Hirai; Masakazu Nagahori; Mitsunobu Matsushita; Kenji Kobayashi; Mitsumasa Kishimoto; Mitsuhiro Takeno; Masanori Tanaka; Nagamu Inoue; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2013-08-18       Impact factor: 7.527

8.  Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).

Authors:  Jung Hoon Lee; Tae Nyeun Kim; Sun Taek Choi; Byung Ik Jang; Kyeong-Cheol Shin; Sam Beom Lee; Young Ran Shim
Journal:  Korean J Intern Med       Date:  2007-03       Impact factor: 3.165

Review 9.  Outcome predictors for intestinal Behçet's disease.

Authors:  Jae Jun Park; Won Ho Kim; Jae Hee Cheon
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

Review 10.  Diagnosis and management of intestinal Behçet's disease.

Authors:  Tadakazu Hisamatsu; Makoto Naganuma; Katsuyoshi Matsuoka; Takanori Kanai
Journal:  Clin J Gastroenterol       Date:  2014-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.